Optiver Holding’s INmune Bio INMB Stock Holding History

Optiver Holding’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-146	Closed	-$165	–	2925
2026 Q1	$165	Buy	146 +4	+3%	+$6	﹤0.01%	2226
2025 Q4	$222	Sell	142 -16	-10%	-$29	﹤0.01%	2345
2025 Q3	$327	Buy	+158	New	+$362	﹤0.01%	2565

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Optiver Holding's INMB Position: Q2 2026 in Review

Optiver Holding sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 146 shares — an estimated $165 sold.

Optiver Holding first reported a position in INMB in Q3 2025 and held it in 3 quarters. The position peaked at $327 in Q3 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

Optiver Holding reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
Optiver Holding sold 146 INmune Bio shares in Q2 2026, an estimated $165.
Optiver Holding first reported a position in INmune Bio in Q3 2025 and held it in 3 quarters.
Optiver Holding's INmune Bio position peaked at $327 in Q3 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.